Global Duloxetine Active Pharmaceutical Ingredients [API] Market

Duloxetine Active Pharmaceutical Ingredients [API] Market Insights

The Duloxetine API Market will rise at a CAGR value of 4.2% during the forecast period of 2020-2026. Duloxetine is a specific inhibitor that comes under the pharmacological class of antidepressants (serotonin and norepinephrine inhibitor). The chemical imbalance in the brain affects the patient’s mental state, leading it to depression and other related mental or neurological disorders. This drug addresses the chemical imbalance state and combats major disorders gradually. Moreover, this drug is used to treat neuropathic pain of those patients suffering from type 1&2 diabetes. Other indications of Duloxetine API drug are Fibromyalgia and Urinary Incontinence. This drug has been approved in Europe for treating urinary incontinence in female patients. Hence, the high prevalence of mental disorders and neurological diseases, rising preference, and awareness of generic drugs, extensive clinical trials on API molecules, will boost the market growth.

Duloxetine API Market: By Type for Drug

Based on the type of drug, the Duloxetine API market is segmented into generic and branded drugs. The generic drugs will have more market share as compared to the branded drugs of Duloxetine. Moreover, the market share of generic drugs is even higher in the Asia-Pacific region about the cost and availability of the type of drug.  

Duloxetine API Market: By Indication

Based on the indication of this drug, the market is segmented into Neurological & Mental Disorders [Major Depressive Disorder, Generalized Anxiety Disorder (GAD) & Neuropathic Pain], Urological Disorder [Urinary Incontinence], and Musculoskeletal Disorder [Fibromyalgia]. The market for neurological and mental disorders is the highest with the fastest growing CAGR too. This is attributed to increasing mental disorders and incidental neurological injuries. However, lately, this drug will be highly adopted for neuropathic pain caused to diabetic patients during the 2020-2026 time frame.

Duloxetine API Market: By Region

The geographical study of the Duloxetine API Market includes Middle East & Africa, CSA, North America, Asia-Pacific, and Europe. North America is a region with the highest number of diabetic patients. Also, the region is highly prevalent for mental disorders, depression, and anxiety disorder. Hence considering the huge target population for the drug, the NA region will be dominating the global market during the forecast period. Furthermore, Asia Pacific will be the fastest-growing region considering the high demand for API drugs and the increasing number of API manufacturers in this region.

Duloxetine API Market Share and Competitor Analysis

Major companies in the market are Teva Pharmaceutical Industries Ltd., Lupin, Sun Pharmaceutical Industries Ltd., Apotex Inc., Aurobindo Pharma, Hetero, Zydus Cadila, Eli Lilly and Company, Shodhana Laboratories, Shionogi Inc., Zhejiang Huahai Pharmaceutical Co., Ltd., Transo-Pharm, UQUIFA, MetroChem API Pvt Ltd., Kinsy SL, RL Fine Chem Pvt. Ltd., Estechpharma Co., Ltd., GPT Pharmaceuticals, LGM Pharma,Nosch Labs Private Limited, JINLAN Pharm-Drugs Technology Co., Ltd, Menovo, Huadong Medicine, Signa and Erregierre among others.

Please note: This is not an exhaustive list of companies profiled in the report.

In November 2018, Sun Pharma procured Pola Pharma, which is into R&D, assembling, and deals will generic drugs in Japan.

In September 2015, Lupin launched the generic Duloxetine 40 mg for the U.S. market.

Check the Press Release on Global Duloxetine Active Pharmaceutical Ingredients [API] Market Report